BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6880505)

  • 1. [Effect of tranquilizers on short-term memory in patients with borderline forms of neuropsychiatric disorders].
    Maksimenko TV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(5):737-40. PubMed ID: 6880505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relation between the effect of tranquilizers and various features of personality structure among patients with borderline states].
    Aleksandrovskiĭ IuA; Khrulenko-Varnitskiĭ IO; Uvarova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1367-76. PubMed ID: 6506985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relation between the dynamics of EEG indices after a single dose of the tranquilizer phenazepam and its efficacy during a course of treatment of patients with borderline neuropsychological disorders].
    Uvarova LG; Titaeva MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(11):1701-9. PubMed ID: 4082841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinico-pharmacological characteristics of combined administration of tranquilizing agents and other psychotropic drugs].
    Aleksandrovskiĭ IuA; Neznamov GG; Tarnavskiĭ IuB; Valueva LN; Sigunova EA
    Farmakol Toksikol; 1982; 45(3):36-41. PubMed ID: 7095127
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sidnocarb correction of the adverse effects of benzodiazepine tranquilizers].
    Valueva LN; Tozhanova NM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(8):92-7. PubMed ID: 6127851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinico-pharmacologic analysis neurovegetotropic activity of tranquilizers].
    Aleksandrovskiĭ IuA; Ben'kovich BI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(5):743-50. PubMed ID: 6464592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicobiochemical parallels in borderline neuropsychic disorders].
    Ushakov GK; Maslova AF; Kostiunina ZG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(11):1663-6. PubMed ID: 6119860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of bemitil pharmacokinetics in realizing its therapeutic efficacy].
    Boĭko SS; Zherdev VP; Neznamov GG
    Farmakol Toksikol; 1991; 54(2):64-6. PubMed ID: 1679400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The positive effect of alprazolam in the treatment of three patients with borderline personality disorder.
    Faltus FJ
    Am J Psychiatry; 1984 Jun; 141(6):802-3. PubMed ID: 6145360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurological complications following therapy with tranquilizers and their drug correction].
    Ben'kovich BI
    Sov Med; 1983; (7):86-9. PubMed ID: 6623185
    [No Abstract]   [Full Text] [Related]  

  • 11. [Predicting the success of a benzodiazepine discontinuation programme: myths or clinical wisdom?].
    Knoop H; Kan CC; Mickers FC; Barnhoorn D
    Tijdschr Psychiatr; 2006; 48(9):695-703. PubMed ID: 17007475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of corticosteroids on short-term and long-term memory.
    Brunner R; Schaefer D; Hess K; Parzer P; Resch F; Schwab S
    Neurology; 2005 Jan; 64(2):335-7. PubMed ID: 15668434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tranquilizers on critical flicker fusion frequency in the visual system.
    Ben'kovich BI; Marshak OV
    Hum Physiol; 1984; 10(6):435-9. PubMed ID: 6544738
    [No Abstract]   [Full Text] [Related]  

  • 14. A momentary assessment study of the reputed emotional phenotype associated with borderline personality disorder.
    Glaser JP; Van Os J; Mengelers R; Myin-Germeys I
    Psychol Med; 2008 Sep; 38(9):1231-9. PubMed ID: 18047769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders.
    Schatzberg AF; Cole JO
    Br J Clin Pharmacol; 1981; 11 Suppl 1(Suppl 1):17S-22S. PubMed ID: 6133529
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phenazepam in the treatment of borderline forms of neuropsychiatric disorders].
    Kalandarishvili AS; Bortnik TL; Berdina ES; Lesovskaia TV; Aleksandrovskiĭ IuA
    Sov Med; 1979 Jul; (7):8-14. PubMed ID: 41325
    [No Abstract]   [Full Text] [Related]  

  • 18. Self-reported memory problems in everyday activities in patients with epilepsy treated with antiepileptic drugs.
    Salas-Puig J; Gil-Nagel A; Serratosa JM; Sánchez-Alvarez JC; Elices E; Villanueva V; Carreño M; Alvarez-Carriles J; Porcel J
    Epilepsy Behav; 2009 Apr; 14(4):622-7. PubMed ID: 19435588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study of the "'rebound syndrome" following discontinuation of prolonged phenazepam administration and possibilities for preventing it].
    Voronina TA; Garibova TL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(7):1056-9. PubMed ID: 7197446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual differences in the effects of clobazam on memory functions--clobazam and memory.
    Koeppen D; Netter P; Fischer C
    Pharmacopsychiatry; 1985 Jan; 18(1):12-4. PubMed ID: 2859617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.